<DOC>
	<DOCNO>NCT00651105</DOCNO>
	<brief_summary>The purpose study assess GLP-1 non-GLP-1 effect LAF237 glucagon secretion , use treatment observation overall glycemic response .</brief_summary>
	<brief_title>Effect LAF237 Glucagon Secretion Patients With Type 2 Diabetes Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Inclusion criterion Type2 Diabetes Patients Male female patient age 30 75 year Type2 Diabetes Mellitus ( T2DM ) otherwise good health Must diagnose T2DM least 6 month prior screen , whose diabetes control diet exercise alone stable dosage ( &gt; 3 month ) metformin HbA1c range 6.5 % 9 % screen Inclusion Criteria Healthy Volunteers Male female subject age 30 75 year , determine good health Normal oral glucose tolerance test ( OGTT ) screen Age , gender weight match subject T2DM Exclusion criterion Type2 Diabetes Patients A history : Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes , e.g. , Cushing 's syndrome acromegaly Acute metabolic diabetic complication ( ketoacidosis hyperosmolar state ( coma ) ) within past 6 month Torsades de Pointes , ventricular tachycardia ventricular fibrillation Any severe hypoglycemic episode within 3 month screen Use follow medication : Antihypertensive lipidlowering agent unless stable dose least 3 month prior screen Chronic insulin treatment ( &gt; 4 week treatment absence intercurrent illness ) within past 6 month Chronic oral/intramuscular/intravenous corticosteroid treatment ( &gt; 7 consecutive day treatment ) within 8 week prior screen Exclusion Criteria Healthy Volunteers First degree relative individual T2DM History gestational diabetes Use prescription medication within 1 month prior dose . Use overthecounter medication vitamin within 14 day prior dose . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Healthy</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Adults</keyword>
</DOC>